AU764103B2 - Long lasting anti-angiogenic peptides - Google Patents

Long lasting anti-angiogenic peptides Download PDF

Info

Publication number
AU764103B2
AU764103B2 AU47748/00A AU4774800A AU764103B2 AU 764103 B2 AU764103 B2 AU 764103B2 AU 47748/00 A AU47748/00 A AU 47748/00A AU 4774800 A AU4774800 A AU 4774800A AU 764103 B2 AU764103 B2 AU 764103B2
Authority
AU
Australia
Prior art keywords
tyr
asp
lys
pro
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU47748/00A
Other languages
English (en)
Other versions
AU4774800A (en
Inventor
Richard Beliveau
Dominique P Bridon
Xicai Huang
Michele Rasamoelisolo
Karen Thibaudeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Biotechnologies Inc
Original Assignee
ConjuChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ConjuChem Inc filed Critical ConjuChem Inc
Publication of AU4774800A publication Critical patent/AU4774800A/en
Application granted granted Critical
Publication of AU764103B2 publication Critical patent/AU764103B2/en
Assigned to CONJUCHEM BIOTECHNOLOGIES INC. reassignment CONJUCHEM BIOTECHNOLOGIES INC. Alteration of Name(s) in Register under S187 Assignors: CONJUCHEM, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
AU47748/00A 1999-05-17 2000-05-17 Long lasting anti-angiogenic peptides Ceased AU764103B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US60/134406 1999-05-17
PCT/IB2000/000763 WO2000070665A2 (en) 1999-05-17 2000-05-17 Long lasting anti-angiogenic peptides

Publications (2)

Publication Number Publication Date
AU4774800A AU4774800A (en) 2000-12-05
AU764103B2 true AU764103B2 (en) 2003-08-07

Family

ID=22463240

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47748/00A Ceased AU764103B2 (en) 1999-05-17 2000-05-17 Long lasting anti-angiogenic peptides

Country Status (9)

Country Link
EP (1) EP1171582A2 (de)
JP (3) JP4209086B2 (de)
CN (2) CN1698881A (de)
AU (1) AU764103B2 (de)
CA (1) CA2373252C (de)
SM (1) SM200000031A (de)
TW (1) TWI300414B (de)
WO (1) WO2000070665A2 (de)
ZA (2) ZA200106676B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011498A2 (en) * 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives
AU2002239414A1 (en) * 2000-11-02 2002-05-27 Bristol-Myers Squibb Company Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
JP4280070B2 (ja) 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
US7741453B2 (en) 2001-05-31 2010-06-22 Conjuchem Biotechnologies, Inc. Long lasting fusion peptide inhibitors for HIV infection
NZ539539A (en) 2002-09-24 2006-11-30 Frontier Biotechnologies Co HIV gp41 c-terminal peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties
CN103897031A (zh) * 2012-12-25 2014-07-02 深圳先进技术研究院 化学修饰的胸腺五肽及其合成方法
CN104892725A (zh) * 2015-05-19 2015-09-09 广州诺威生物技术有限公司 一种萘乙酰胺新化合物
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
CN110372781B (zh) * 2019-07-29 2021-11-16 深圳佳肽生物科技有限公司 恩夫韦肽的制备方法和应用
CN117186187B (zh) * 2023-07-12 2024-05-31 中国医学科学院病原生物学研究所 一种抗呼吸道合胞病毒膜融合抑制剂及其药物用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602290B1 (de) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
HUP9900979A3 (en) * 1995-12-13 2001-10-29 Children S Medical Ct Corp Bos Endothelial cell proliferation inhibitor and method of use
JP4426650B2 (ja) * 1996-05-03 2010-03-03 アボット・ラボラトリーズ 新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法
JP2001522863A (ja) * 1997-11-07 2001-11-20 コンジュケム，インコーポレーテッド Ｒｇｄ含有ペプチドおよび内因性担体の新規コンジュゲート
ATE218892T1 (de) * 1997-11-07 2002-06-15 Conjuchem Inc Affinitätsmarkierer für menschliches serum albumin
IL133053A0 (en) * 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives

Also Published As

Publication number Publication date
JP2009143941A (ja) 2009-07-02
EP1171582A2 (de) 2002-01-16
TWI300414B (en) 2008-09-01
CN1698881A (zh) 2005-11-23
ZA200109110B (en) 2002-06-13
ZA200106676B (en) 2002-07-19
WO2000070665A2 (en) 2000-11-23
JP2008110986A (ja) 2008-05-15
SM200000031B (it) 2001-11-21
CN101289500A (zh) 2008-10-22
SM200000031A (it) 2001-11-21
WO2000070665A3 (en) 2001-04-19
CA2373252C (en) 2007-08-07
CA2373252A1 (en) 2000-11-23
TW200524957A (en) 2005-08-01
AU4774800A (en) 2000-12-05
JP4209086B2 (ja) 2009-01-14
JP2003500341A (ja) 2003-01-07

Similar Documents

Publication Publication Date Title
US7741286B2 (en) Long lasting anti-angiogenic peptides
US8080516B2 (en) Long lasting synthetic exendin-4 peptide conjugates
US7112567B2 (en) Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
US20110166061A1 (en) Long lasting fusion peptide inhibitors for hiv infection
JP2008110986A (ja) 長期持続性抗新脈管形成ペプチド
AU5027100A (en) Long lasting fusion peptide inhibitors of viral infection
US7144854B1 (en) Long lasting anti-angiogenic peptides

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)